Elafibranor - Genfit

Drug Profile

Elafibranor - Genfit

Alternative Names: GFT505

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genfit
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Primary biliary cirrhosis
  • No development reported Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2018 Genfit completes enrolment in its phase IIa trial for Primary biliary cirrhosis in USA and Europe
  • 24 Jun 2018 Biomarkers information updated
  • 28 Mar 2018 Preclinical trials in Non-alcoholic steatohepatitis (Combination therapy) in France (PO) before March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top